Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

Sandoz, Teva And Viatris Adopt Differing Strategies With Regard To Innovation

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

Winning hand at blackjack, betting concept
Which firms will end up with a winning hand? • Source: Shutterstock

Competitive pressures are par for the course in the off-patent industry. The generics and biosimilars sector is built on the premise of multi-source competition, meaning that multiple players in the market will always be vying for share, working out how to keep costs as low as possible, and surviving on margins that are often slim.

In recent years, the top three companies in the sector – Sandoz Inc., Teva Pharmaceutical Industries Ltd. and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.